Results 251 to 260 of about 187,398 (301)

Transendocardial injection of expanded autologous CD34+ cells after myocardial infarction: Design of the EXCELLENT trial

ESC Heart Failure, Volume 12, Issue 2, Page 1455-1463, April 2025.
Abstract Aims The extent of irreversible cardiomyocyte necrosis after acute myocardial infarction (AMI) is a major determinant of residual left ventricular (LV) function and clinical outcome. Cell therapy based on CD34+ cells has emerged as an option to help repair the myocardium and to improve outcomes.
Jerome Roncalli, François Roubille, Nicolas Meyer, Giulio Pompilio, Lionel Leroux, Philippe Henon, Guillaume Trebuchet, Anthony Criquet, Matthieu de Kalbermatten, Eric Saloux, Alain Manrique, Pierre‐Yves Marie, Deepak L. Bhatt, Scott D. Solomon, Gilles Montalescot, David E. Newby, Faiez Zannad, on behalf of the EXCELLENT Trial Investigators   +17 more
wiley   +1 more source

Identification, characterisation and outcomes of pre-atrial fibrillation in heart failure with reduced ejection fraction. [PDF]

ESC Heart Fail
Helbitz A, Nadarajah R, Mu L, Larvin H, Ismail H, Wahab A, Thompson P, Harrison P, Harris M, Joseph T, Plein S, Petrie M, Metra M, Wu J, Swoboda P, Gale CP.   +15 more
europepmc   +1 more source

Phenotyping patients with chronic obstructive pulmonary disease and heart failure

ESC Heart Failure, Volume 12, Issue 2, Page 900-911, April 2025.
Central illustration. Abbreviations: ACEi, angiotensin‐converting enzyme inhibitor; ARB, angiotensin receptor blocker; ARNi, angiotensin‐receptor‐neprilysin inhibitor; CI, confidence interval; COPD, chronic obstructive pulmonary disease; CRT, cardiac resynchronization therapy; CV, cardiovascular; EF, ejection fraction; eGFR, estimated glomerular ...
Peter Moritz Becher, Felix Lindberg, Lina Benson, Camilla Hage, Ulf Dahlström, Stephan Rosenkranz, Francesco Cosentino, Giuseppe M.C. Rosano, Stefan Blankenberg, Paulus Kirchhof, Frieder Braunschweig, Lars H. Lund, Gianluigi Savarese   +12 more
wiley   +1 more source

Phenomapping in Heart Failure With Reduced Ejection Fraction to Identify Subpopulations With High Residual Risk: A VICTORIA Substudy. [PDF]

Circ Heart Fail
Shah P, Zheng Y, Pieske B, Melenovsky V, Lam CSP, Sliwa K, Butler J, Ezekowitz JA, deFilippi CR, O'Connor CM, Sandhu RK, Roessig L, Tromp J, Westerhout CM, Voors AA, Armstrong PW, VICTORIA Study Group.   +16 more
europepmc   +1 more source

Myocardial revascularization in heart failure with reduced ejection fraction

Deutsches Ärzteblatt international
Haring, Bernhard, Bauersachs, Johann, Frey, Norbert, Hoppe, Uta C., Doenst, Torsten, Böhm, Michael   +5 more
openaire   +1 more source

Levosimendan in Decompensated Heart Failure with Reduced Ejection Fraction in Older Adults: A Systematic Review of Safety and Efficacy. [PDF]

Medicines (Basel)
Zavaleta-Monestel E, Mora-Jiménez J, Cruz-Mora K, Martinez-Vargas E, Díaz-Madriz JP, Arguedas-Chacón S, Fallas-Mora A, Wu-Chin C, Chaverrí-Fernandez JM.   +8 more
europepmc   +1 more source

Finerenone and semaglutide: Role in heart failure with reduced ejection fraction. [PDF]

World J Cardiol
Gulzar MAR.
europepmc   +1 more source

Gut Microbiota-Derived Metabolite and Heart Failure with Reduced Ejection Fraction (HFrEF): Elevated Trimethylamine N-Oxide (TMAO) as a Potential Biomarker. [PDF]

Int J Mol Sci
Kuan SW, Ng WL, Loch A, Chua KH, Tan KK, Kee BP.   +5 more
europepmc   +1 more source

Oral nitrate-reducing capacity and aerobic fitness are impaired in older individuals with heart failure with reduced ejection fraction. [PDF]

Am J Physiol Heart Circ Physiol
Stahl ME, Grammer EE, Weltman A, Burleigh MC, Derella CC, Abbate A, Denicolai M, Allen JD.   +7 more
europepmc   +1 more source